Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL versus investigator's choice chemotherapy in advanced melanoma
CTR20244769Phase 2Active
- Sponsor
- Juncell Therapeutics
- Start
- Jan 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nolgileucel in melanoma (2 arms), sponsored by Juncell Therapeutics. Primary endpoint: Progression-free survival. Started Jan 2025; status: active.
02
Drugs
nolgileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20244769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244769.